- Home
- JRVR vs MOLN Comparison
JRVR vs MOLN Comparison
Compare JRVR & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | JRVR | MOLN |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.9M | 170.5M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JRVR | MOLN |
|---|---|---|
| Price | $3.52 | $3.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $4.72 | ★ $10.36 |
| AVG Volume (30 Days) | ★ 296.9K | 1.6K |
| Earning Date | 11-02-2026 | 10-29-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ 125.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $687,614,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $450.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.36 | $3.53 |
| 52 Week High | $7.20 | $5.36 |
Technical Indicators
Market Signals| Indicator | JRVR | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 32.80 | 41.35 |
| Support Level | N/A | N/A |
| Resistance Level | $4.26 | $4.35 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 22.13 | 3.09 |
Price Performance
Historical ComparisonAbout JRVR James River Group Holdings Ltd.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.